164 related articles for article (PubMed ID: 32839218)
1. An Open-Label Study of the Impact of Hepatic Impairment on the Pharmacokinetics and Safety of Single Oral and Intravenous Doses of Omadacycline.
Kovacs SJ; Ting L; Praestgaard J; Sunkara G; Sun H; Stein DS; Tanaka SK; Villano S
Antimicrob Agents Chemother; 2020 Oct; 64(11):. PubMed ID: 32839218
[TBL] [Abstract][Full Text] [Related]
2. Omadacycline: A Novel Oral and Intravenous Aminomethylcycline Antibiotic Agent.
Zhanel GG; Esquivel J; Zelenitsky S; Lawrence CK; Adam HJ; Golden A; Hink R; Berry L; Schweizer F; Zhanel MA; Bay D; Lagacé-Wiens PRS; Walkty AJ; Lynch JP; Karlowsky JA
Drugs; 2020 Feb; 80(3):285-313. PubMed ID: 31970713
[TBL] [Abstract][Full Text] [Related]
3. Randomized, Open-Label Study of the Pharmacokinetics and Safety of Oral and Intravenous Administration of Omadacycline to Healthy Subjects.
Sun H; Ting L; Machineni S; Praestgaard J; Kuemmell A; Stein DS; Sunkara G; Kovacs SJ; Villano S; Tanaka SK
Antimicrob Agents Chemother; 2016 Dec; 60(12):7431-7435. PubMed ID: 27736760
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and Safety of Omadacycline in Subjects with Impaired Renal Function.
Berg JK; Tzanis E; Garrity-Ryan L; Bai S; Chitra S; Manley A; Villano S
Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29158281
[TBL] [Abstract][Full Text] [Related]
5. Omadacycline: A Review of the Clinical Pharmacokinetics and Pharmacodynamics.
Rodvold KA; Burgos RM; Tan X; Pai MP
Clin Pharmacokinet; 2020 Apr; 59(4):409-425. PubMed ID: 31773505
[TBL] [Abstract][Full Text] [Related]
6. Omadacycline Oral Dosing and Pharmacokinetics in Community-Acquired Bacterial Pneumonia and Acute Bacterial Skin and Skin Structure Infection.
Leviton IM; Amodio-Groton M
Clin Drug Investig; 2022 Mar; 42(3):193-197. PubMed ID: 35192150
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of omadacycline for treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections in patients with mild-to-moderate renal impairment.
Cornely OA; File TM; Garrity-Ryan L; Chitra S; Noble R; McGovern PC
Int J Antimicrob Agents; 2021 Feb; 57(2):106263. PubMed ID: 33326848
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and Pharmacodynamics of Oral and Intravenous Omadacycline.
Rodvold KA; Pai MP
Clin Infect Dis; 2019 Aug; 69(Suppl 1):S16-S22. PubMed ID: 31367744
[TBL] [Abstract][Full Text] [Related]
9. Omadacycline: A New Tetracycline Antibiotic.
Dougherty JA; Sucher AJ; Chahine EB; Shihadeh KC
Ann Pharmacother; 2019 May; 53(5):486-500. PubMed ID: 30917674
[TBL] [Abstract][Full Text] [Related]
10. Once-daily oral omadacycline versus twice-daily oral linezolid for acute bacterial skin and skin structure infections (OASIS-2): a phase 3, double-blind, multicentre, randomised, controlled, non-inferiority trial.
O'Riordan W; Cardenas C; Shin E; Sirbu A; Garrity-Ryan L; Das AF; Eckburg PB; Manley A; Steenbergen JN; Tzanis E; McGovern PC; Loh E;
Lancet Infect Dis; 2019 Oct; 19(10):1080-1090. PubMed ID: 31474458
[TBL] [Abstract][Full Text] [Related]
11. Safety and Pharmacokinetics of the Aminomethylcycline Antibiotic Omadacycline Administered to Healthy Subjects in Oral Multiple-Dose Regimens.
Bundrant LA; Tzanis E; Garrity-Ryan L; Bai S; Chitra S; Manley A; Villano S
Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29180524
[TBL] [Abstract][Full Text] [Related]
12. The Effect of Verapamil, a P-gp Inhibitor, on the Pharmacokinetics, Safety, and Tolerability of Omadacycline in Healthy Adults: A Phase I, Open-Label, Single-Sequence Study.
Hunt TL; Tzanis E; Bai S; Manley A; Chitra S; McGovern PC
Eur J Drug Metab Pharmacokinet; 2021 Jan; 46(1):85-92. PubMed ID: 33180250
[TBL] [Abstract][Full Text] [Related]
13. Omadacycline: First Global Approval.
Markham A; Keam SJ
Drugs; 2018 Dec; 78(18):1931-1937. PubMed ID: 30471003
[TBL] [Abstract][Full Text] [Related]
14. Surveillance of omadacycline activity tested against clinical isolates from the United States and Europe: Results from the SENTRY Antimicrobial Surveillance Programme, 2017.
Huband MD; Pfaller MA; Shortridge D; Flamm RK
J Glob Antimicrob Resist; 2019 Dec; 19():56-63. PubMed ID: 30825698
[TBL] [Abstract][Full Text] [Related]
15. An Integrated Safety Summary of Omadacycline, a Novel Aminomethylcycline Antibiotic.
Opal S; File TM; van der Poll T; Tzanis E; Chitra S; McGovern PC
Clin Infect Dis; 2019 Aug; 69(Suppl 1):S40-S47. PubMed ID: 31367740
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and safety of galantamine in subjects with hepatic impairment and healthy volunteers.
Zhao Q; Iyer GR; Verhaeghe T; Truyen L
J Clin Pharmacol; 2002 Apr; 42(4):428-36. PubMed ID: 11936568
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics, Safety, and Clinical Outcomes of Omadacycline in Women with Cystitis: Results from a Phase 1b Study.
Overcash JS; Bhiwandi P; Garrity-Ryan L; Steenbergen J; Bai S; Chitra S; Manley A; Tzanis E
Antimicrob Agents Chemother; 2019 May; 63(5):. PubMed ID: 30858208
[TBL] [Abstract][Full Text] [Related]
18. Omadacycline for Community-Acquired Bacterial Pneumonia.
Stets R; Popescu M; Gonong JR; Mitha I; Nseir W; Madej A; Kirsch C; Das AF; Garrity-Ryan L; Steenbergen JN; Manley A; Eckburg PB; Tzanis E; McGovern PC; Loh E
N Engl J Med; 2019 Feb; 380(6):517-527. PubMed ID: 30726692
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics, Safety and Pharmacokinetics/Pharmacodynamics Analysis of Omadacycline in Chinese Healthy Subjects.
Yang H; Huang Z; Chen Y; Zhu Y; Cao G; Wang J; Guo Y; Yu J; Wu J; Liu L; Deng J; Liu J; Reinhart H; Zhang J; Wu X
Front Pharmacol; 2022; 13():869237. PubMed ID: 35529438
[No Abstract] [Full Text] [Related]
20. Omadacycline: A Novel Tetracycline Derivative With Oral and Intravenous Formulations.
Watkins RR; Deresinski S
Clin Infect Dis; 2019 Aug; 69(5):890-896. PubMed ID: 30893428
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
